Steven Seedhouse
Stock Analyst at Raymond James
(0.54)
# 3,924
Out of 4,883 analysts
172
Total ratings
30.3%
Success rate
-27.83%
Average return
Main Sectors:
Stocks Rated by Steven Seedhouse
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MIRM Mirum Pharmaceuticals | Maintains: Strong Buy | $73 → $77 | $48.88 | +57.53% | 19 | May 13, 2025 | |
| KRRO Korro Bio | Initiates: Overweight | $74 | $13.27 | +457.65% | 2 | Apr 29, 2025 | |
| WVE Wave Life Sciences | Initiates: Overweight | $10 | $6.78 | +47.49% | 3 | Apr 29, 2025 | |
| PHVS Pharvaris | Initiates: Overweight | $28 | $17.83 | +57.04% | 1 | Apr 29, 2025 | |
| ATXS Astria Therapeutics | Initiates: Overweight | $47 | $5.75 | +717.39% | 1 | Apr 29, 2025 | |
| IFRX InflaRx | Initiates: Overweight | $10 | $0.81 | +1,142.24% | 14 | Apr 29, 2025 | |
| BCRX BioCryst Pharmaceuticals | Initiates: Overweight | $20 | $9.02 | +121.85% | 1 | Apr 29, 2025 | |
| VKTX Viking Therapeutics | Initiates: Overweight | $104 | $27.66 | +275.99% | 19 | Apr 28, 2025 | |
| QTTB Q32 Bio | Downgrades: Outperform | $90 → $22 | $1.46 | +1,406.85% | 2 | Dec 11, 2024 | |
| DNTH Dianthus Therapeutics | Maintains: Outperform | $51 → $56 | $18.10 | +209.48% | 3 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $53 → $49 | $10.08 | +386.11% | 10 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Strong Buy | $6 → $14 | $2.12 | +561.94% | 6 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $93 | $111.44 | -16.55% | 9 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $57 → $68 | $23.62 | +187.89% | 3 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $67 → $106 | $17.72 | +498.19% | 15 | Jan 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $12 → $15 | $4.16 | +261.01% | 2 | Jan 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $27 → $56 | $8.90 | +529.21% | 4 | Jan 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $19 → $18 | $0.29 | +5,993.31% | 8 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $78 → $57 | $10.65 | +435.21% | 10 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $20 → $22 | $1.12 | +1,873.09% | 2 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $17 | $2.60 | +553.85% | 6 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $35 | $2.87 | +1,121.64% | 4 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $38 | $44.57 | -14.74% | 2 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $30 → $71 | $29.29 | +142.40% | 4 | Dec 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $5 | $1.22 | +311.52% | 5 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $38 | $24.00 | +58.33% | 2 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $13.71 | - | 7 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.80 | - | 5 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $285 → $270 | $15.78 | +1,611.03% | 1 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $132.88 | - | 2 | Apr 23, 2020 |
Mirum Pharmaceuticals
May 13, 2025
Maintains: Strong Buy
Price Target: $73 → $77
Current: $48.88
Upside: +57.53%
Korro Bio
Apr 29, 2025
Initiates: Overweight
Price Target: $74
Current: $13.27
Upside: +457.65%
Wave Life Sciences
Apr 29, 2025
Initiates: Overweight
Price Target: $10
Current: $6.78
Upside: +47.49%
Pharvaris
Apr 29, 2025
Initiates: Overweight
Price Target: $28
Current: $17.83
Upside: +57.04%
Astria Therapeutics
Apr 29, 2025
Initiates: Overweight
Price Target: $47
Current: $5.75
Upside: +717.39%
InflaRx
Apr 29, 2025
Initiates: Overweight
Price Target: $10
Current: $0.81
Upside: +1,142.24%
BioCryst Pharmaceuticals
Apr 29, 2025
Initiates: Overweight
Price Target: $20
Current: $9.02
Upside: +121.85%
Viking Therapeutics
Apr 28, 2025
Initiates: Overweight
Price Target: $104
Current: $27.66
Upside: +275.99%
Q32 Bio
Dec 11, 2024
Downgrades: Outperform
Price Target: $90 → $22
Current: $1.46
Upside: +1,406.85%
Dianthus Therapeutics
Nov 8, 2024
Maintains: Outperform
Price Target: $51 → $56
Current: $18.10
Upside: +209.48%
Nov 8, 2024
Maintains: Strong Buy
Price Target: $53 → $49
Current: $10.08
Upside: +386.11%
Oct 29, 2024
Upgrades: Strong Buy
Price Target: $6 → $14
Current: $2.12
Upside: +561.94%
Jul 8, 2024
Upgrades: Outperform
Price Target: $93
Current: $111.44
Upside: -16.55%
May 10, 2024
Maintains: Strong Buy
Price Target: $57 → $68
Current: $23.62
Upside: +187.89%
Jan 11, 2024
Maintains: Strong Buy
Price Target: $67 → $106
Current: $17.72
Upside: +498.19%
Jan 9, 2024
Maintains: Strong Buy
Price Target: $12 → $15
Current: $4.16
Upside: +261.01%
Jan 4, 2024
Maintains: Strong Buy
Price Target: $27 → $56
Current: $8.90
Upside: +529.21%
Nov 14, 2023
Maintains: Outperform
Price Target: $19 → $18
Current: $0.29
Upside: +5,993.31%
Nov 10, 2023
Maintains: Outperform
Price Target: $78 → $57
Current: $10.65
Upside: +435.21%
Aug 15, 2023
Maintains: Strong Buy
Price Target: $20 → $22
Current: $1.12
Upside: +1,873.09%
Jun 13, 2023
Upgrades: Outperform
Price Target: $17
Current: $2.60
Upside: +553.85%
May 5, 2023
Maintains: Outperform
Price Target: $33 → $35
Current: $2.87
Upside: +1,121.64%
May 5, 2023
Upgrades: Outperform
Price Target: $38
Current: $44.57
Upside: -14.74%
Dec 15, 2022
Maintains: Strong Buy
Price Target: $30 → $71
Current: $29.29
Upside: +142.40%
Dec 7, 2022
Maintains: Outperform
Price Target: $15 → $5
Current: $1.22
Upside: +311.52%
Nov 9, 2022
Maintains: Outperform
Price Target: $30 → $38
Current: $24.00
Upside: +58.33%
Aug 10, 2022
Downgrades: Underperform
Price Target: n/a
Current: $13.71
Upside: -
May 18, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $1.80
Upside: -
Aug 6, 2021
Maintains: Outperform
Price Target: $285 → $270
Current: $15.78
Upside: +1,611.03%
Apr 23, 2020
Downgrades: Sell
Price Target: n/a
Current: $132.88
Upside: -